peterschreiber.media Oppenheimer started coverage of Benitec Biopharma ( NASDAQ: BNTC ) at outperform, citing its gene therapy candidate BB-301 for the treatment of ocular pharyngeal muscular dystrophy, or OPMD. The investment bank said it sees worldwide sales of around $438M for BB-301 in 2030, as it.
